Global X CleanTech vs Incyte Corporation — how do they compare? Global X CleanTech trades at $58.44, while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| CTEC | INCY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $129.93 |
52-Week Low | $41.08 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Trailing returns across standard periods
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →